Bladder Tumor Heterogeneity: The Impact on Clinical Treatment
Open Access
- 21 March 2015
- journal article
- review article
- Published by S. Karger AG in Urologia Internationalis
- Vol. 95 (1), 1-8
- https://doi.org/10.1159/000370165
Abstract
Bladder cancer relapse and treatment failure in most patients have often been attributed to chemoresistance in tumor cells and metastasis. Emerging evidence indicates that tumor heterogeneity may play an equally important role and extends to virtually all measurable properties of cancer cells. Although the idea of tumor heterogeneity is not new, little attention has been paid to applying it to understand and control bladder cancer progression. With the development of biotechnology, such as Gene sequencing, recent advances in understanding its generation model, original basis, consequent problems, and derived therapies provide great potential for tumor heterogeneity to be considered a new insight in the treatment of bladder cancers.Keywords
This publication has 55 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- The Life History of 21 Breast CancersCell, 2012
- Single-Cell Exome Sequencing Reveals Single-Nucleotide Mutation Characteristics of a Kidney TumorCell, 2012
- Clonal evolution in cancerNature, 2012
- Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencingNature, 2012
- Bone Marrow-Derived Myofibroblasts Contribute to the Mesenchymal Stem Cell Niche and Promote Tumor GrowthCancer Cell, 2011
- Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer DevelopmentCell, 2011
- The patterns and dynamics of genomic instability in metastatic pancreatic cancerNature, 2010
- Genome remodelling in a basal-like breast cancer metastasis and xenograftNature, 2010
- Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomasNature, 2007